Atara Biotherapeutics (ATRA) Cash from Financing Activities (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Cash from Financing Activities came in at $3.0 million in Q1 2026, up 1280.4% YoY from $213778.6 in Q1 2025, and up 98466.67% on a QoQ basis from -$3000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Cash from Financing Activities data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 1280.4% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (down 44.69% YoY) and the FY2025 annual result came in at $16.1 million, down 72.85% from the prior year.
- Cash from Financing Activities climbed to $3.0 million in Q1 2026, from -$3000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $35.8 million in Q3 2024 to a low of -$328000.0 in Q4 2024.
- A 5-year average of $7.8 million and a median of $1.0 million in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 17308.17% in 2024, down 168.79% in 2024.
- Tracing ATRA's Cash from Financing Activities over 5 years: stood at $32.3 million in 2022, then slumped by 95.32% to $1.5 million in 2023, then sank by 121.69% to -$328000.0 in 2024, then soared by 99.09% to -$3000.0 in 2025, then soared by 98466.67% to $3.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $3.0 million (Q1 2026), -$3000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | 4.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.83 Mn |
| Jun 30, 2026 | 4.83 Mn |
| Mar 31, 2026 | 2.95 Mn |
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | -3,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | 1.05 Mn |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 15.30 Mn |
| Jun 30, 2025 | 15.30 Mn |
| Mar 31, 2025 | -250,000.00 |
| Mar 31, 2025 | -250,000.00 |
| Dec 31, 2024 | -328,000.00 |
| Dec 31, 2024 | -328,000.00 |
| Sep 30, 2024 | 35.79 Mn |
| Sep 30, 2024 | 35.79 Mn |
| Jun 30, 2024 | -324,000.00 |
| Jun 30, 2024 | -324,000.00 |
| Mar 31, 2024 | 24.14 Mn |
| Mar 31, 2024 | 24.14 Mn |